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1. Introduction
Although major progress has been made to reduce global incidence of drug-susceptible
tuberculosis (TB), the emergence of multidrug-resistant (MDR) and extensively drug-resistant
(XDR) TB over the past decade presents an unprecedented public health challenge to which
countries of concern are responding far too slowly. Indeed, a recent WHO TB surveillance
report indicates the highest global level of drug-resistance ever recorded, which affected
disproportionately developing countries with an estimated 440,000 MDR-TB cases worldwide
resulting in 150,000 deaths in 2009 [1]. Even more troubling is being the recent emergence of
new strains of totally drug-resistant M. tuberculosis (Mtb), currently occurring in densely
populated cities such as Teheran (Iran) [2] and Mumbai (India) [3]. Given that an untreated
TB patient can infect up to 15 contacts in a year in overcrowded areas [4], it is highly likely that
totally drug-resistant TB will continues spreading and one would worry that TB will again
become an incurable disease.
While part of the increase in drug resistance can be attributed to difficulty in treating patients
who are double infected with HIV, which represent about 13% of total TB cases [5], detailed
field studies revealed that the emergence drug-resistant TB is clearly a direct consequence of
misdiagnosis and mismanagement of drug susceptible TB, which result in only a fraction of
TB patients getting correct diagnosis and appropriate therapy ([6,7] and Fig.1). In other words,
“Resistance is man-made, caused by exposure to the wrong treatment, the wrong regimen, the
wrong treatment duration” says TB expert Giovanni Miglio [8]. Therefore, a comprehensive
approach to ensure rapid detection, proper treatment and public health measures needs to be
applied globally to cure TB patients and prevent further transmission of the disease. This
chapter discusses various challenges facing the management of drug resistant TB and presents
the efforts of WHO and its partners for the development of strategies and guidelines for
optimal TB control.
© 2013 Hmama; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. Misdiagnosis and mismanagement can result in only fraction of TB patients getting correct diagnosis, appro‐
priate therapy, and positive outcomes. Reprinted from Ref. 9 with permission from Dr. Madhukar Pai.
2. Standard treatment for drug-susceptible TB
Symptoms associated with active TB are generally defined as loss of weight and energy, poor
appetite, fever, a productive cough, and night sweats. Although highly suggestive of TB, such
symptoms might easily be assigned to another disease. Therefore accurate diagnosis is
important before initiating drug therapy. The current standard laboratory test consists on the
analysis of 3 sputum specimens for acid-fast bacilli smears and culture, with nucleic acid
amplification performed on at least 1 specimen [10].
In 1994, the WHO introduced the DOTS (Directly Observed Treatment, Short-course) as a
major plan to control TB globally [11]. The DOTS strategy focuses on five main points of action:
1) government commitment to control TB, 2) diagnosis based on sputum-smear microscopy
tests done on patients with TB symptoms, 3) direct observation short-course chemotherapy
treatments, 4) a continuous supply of drugs, and 5) standardized reporting and recording of
cases and treatment outcomes [11]. The standard short course (SSC) treatment recommended
by WHO [12] consists of 2 months of intensive phase of daily oral administration of isoniazid
(INH), rifampicin (RMP), pyrazinamide (PZA) and ethambutol (EMB) followed by 4 months
continuous phase of daily INH and RMP alone.
INH is only active against growing tubercle bacilli [13]. RMP is active against both growing
and stationary phase bacilli with low metabolic activity and is associated with high sterilizing
activity in vivo [14]. PZA plays a unique role in shortening TB treatment from the previous 12
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months to 6 months because it kills the persistent Mtb population in the lung [15]. EMB is
active against growing Mtb but has no effect on dormant bacilli. The combination of drugs
acting at different stages of the Mtb life cycle during SSC therapy has been successful in TB
treatment in most endemic countries when patients adhere to a fairly strict daily regimen. SSC
therapy causes minor or no side effects and is affordable, costing less than $40 for a full course
of treatment. Side effects, if they occur, are manageable and usually do not result in the
interruption of the treatment.
Aproximately 90% of people infected with Mtb develop an efficient immune response that
successfully contains the infection but unfortunately without killing all the bacteria. Surviving
bacteria persist in the lung as non-replicative (i.e. dormant) organisms [16]. In this stage of
latent TB infection (LTBI), people do not exhibit TB symptoms and cannot pass the infection
on to other individuals. However, in weakened immune system conditions (old age, HIV
infection or therapeutic immunosupression), dormant bacteria revert into dividing organisms
leading to TB reactivation [16].
LTBI is highly suspected in individuals previously exposed to those with known active TB,
which would include people in hospitals, homeless shelters and prisons, or people having
recently traveled to countries where TB is highly endemic. The stage of clinical latency is of
surpassing importance for TB control as most cases of active TB arise from the vast reservoir
of the latently infected population [17]. In fact, it estimated that the infection reactivates and
cause active TB in approximately 5 to 10% of latently infected persons [18].
Purified protein derivative (PPD) skin test (also known as the Mantoux test) is the major
diagnostic tool used to identify LTBI patients. A positive skin reaction to the PPD test reflects
a local cellular immune response, which is interpreted as recent or remote exposure to the TB
bacterium. However, despite its usefulness and simplicity, the PPD test have a low predictive
value since false-positive reactions can occur as a result of previous BCG vaccination or
sensitization to environmental mycobacteria [19,20,21]. In fact, the skin test uses a crude mix
of Mtb antigens shared among many mycobacterial species. As a replacement for the PPD test,
new interferon-gamma release assays (IGRAs) have been recently developed and shown to be
more accurate for LTB diagnosis [22]. IGRAs measure ex-vivo production of IFN-gamma by
circulating T cells in whole blood in response to more specific Mtb antigens such as ESAT6,
CFP10 and TB7.7.
Although LTBI is symptom-free and non contagious, many countries have adopted its
treatment in order to reduce the risk of infection progression to active TB and the spread of
the disease to the general population. Six to 9 month treatment with INH alone was proven to
be effective and safe [10]. Unfortunately, if LTBI results from exposure to a person with MDR-
or TB XDR-TB, preventive treatment options are very limited or may not be possible. In both
active and latent TB cases, it is crucial that health care providers make every effort to ensure
that infected persons complete the entire course of treatment. They must explain clearly the
benefit of the treatment and also possible side effects (or drug interactions). Additionally, They
should identify potential barriers to the course of treatment, which will help to establish an
efficient plan to ensure adherence.
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Understanding the mechanisms of TB latency is crucial to development of better control
strategies. Infection with Mtb occurs initially in alveolar macrophage, in which the bacteria
replicate and induce cytokines that initiate the inflammatory response in the lungs, leading
ultimately to the formation of granuloma [23]. Granuloma is defined as an immune structure
consisting of connective tissue, lymphocytes and activated macrophages, which has a central
necrotic core containing extracellular bacteria. Within the granuloma the bacterium is exposed
to multiple stresses that include, among others, hypoxic, nutrient limiting, oxidative, nitrosa‐
tive and acidic conditions [24,25], which trigger a genetic program controlled by the transcrip‐
tion factor DosR [25]. The later regulates the development of a quiescent physiological state,
which maintains viability of non-dividing bacteria for extended periods of time. The granu‐
loma contains the infection and prevents its spread to other organs [26]. However, dormant
bacteria are capable of reactivation controlled by Rpf (resuscitation promoting factor) genes,
which is associated with reversal of the non-replicating state into a metabolically active
growing and dividing bacteria [27]. Thus, life-long immunity is not gained by a first episode
of active TB disease and the disease may develop again at a later stage, either through relapse
with the same strain or reinfection with a new strain.
Deciphering the molecular basis of dormancy and reactivation is therefore necessary for
developing more efficient TB therapies. Adjuncts of agents that would block transitions
between active growth, dormancy, and resuscitation or kill effectively dormant bacteria can
significantly enhance the efficacy of current treatments for latent infection. Such agents would
also shorten the treatment duration of active TB.
3. Molecular basis of Mtb resistance to SSC drugs
The frequency of spontaneous mutations that confer resistance to an individual TB drugs in
vitro are well known and vary from 1 in 105 (EMB) to 1 in 1010 (RMP) [28].
Resistance to INH: INH is a drug precursor that is activated by Mtb catalase-peroxidase enzyme
(KatG) to generate a range of highly reactive species [29]. Active INH targets essentially enoyl-
acyl carrier protein reductase (InhA enzyme), which is involved in mycolic acid synthesis [29].
Resistance to INH occurs more frequently than for most anti-TB drugs, at a frequency of 1 in
106 bacilli in vitro [13]. Clinical isolates of INH-resistant Mtb often lose catalase and peroxidase
activities due to KatG S315T mutation [30]. Resistance to INH can also occur through mutations
in the promoter region of inhA, causing overexpression of InhA, or by mutations at the InhA
active site, lowering InhA affinity for INH [31]. katG mutation can be associated with inhA
mutations, leading to higher levels of INH resistance [32].
Resistance to RMP: RMP interferes with RNA synthesis by binding to the β subunit of myco‐
bacterial RNA polymerase, which is encoded by rpoB. Mtb resistance to RMP occurs at a
frequency of 10−7 to 10−8 as a result of mutations in rpoB. Mutations at positions 531, 526 and
516 in rpoB are among the most frequent (96%) in RMP-resistant strains [33].
Resistance to PZA: PZA requires conversion to its active form, pyrazinoic acid (POA), by the
pyrazinamidase/nicotinamidase enzyme encoded by Mtb pncA, which then permeates
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through the membrane, disrupts bacterial membrane potential and affects membrane trans‐
port [34]. PZA resistance is linked to defective pyrazinamidase/nicotinamidase activity, which
results from mutations that might occur at different regions (3-17, 61-85 and 132-142) of pncA
[34]. While most PZA-resistant strains (72–97%) have pncA mutations, some do not have pncA
mutations but rather express defective pyrazinamidase/nicotinamidase activity [13], which
suggests possible mutations in a putative pncA regulatory gene, yet to be identified.
Resistance to EMB: Arabinosyl transferase, encoded by embB, an enzyme involved in the
synthesis of cell wall arabinogalactan, has been proposed as the target of EMB in Mtb [35].
Mutation to EMB resistance occurs at a frequency of 10−5 [13]. The embB codon 306 mutation
account for only 68% EMB resistant strains [36], suggesting that there may be other mecha‐
nisms of EMB resistance. Therefore, further studies are needed to identify potential new
mechanisms of EMB resistance.
Because the mutations described above are unlinked, the probability of developing bacillary
resistance to 4 drugs used simultaneously is unlikely. Clinical drug-resistant TB is definitely
the result of genetic mutation amplification through mismanagement of the TB disease. This
includes intermittent therapy due to irregular drug supply, inappropriate drug prescriptions
and most importantly poor patient adherence to treatment [37]. Sequential accumulation of
mutations in different genes involved in individual drug resistance results in the emergence
of multiple drug resistance.
4. Diagnosis of multidrug resistant tuberculosis
Conventional culturing of the etiologic agent combined with drug susceptibility testing (DST)
is the ‘gold standard’ for diagnosing drug resistant TB in order to initiate adequate treatment.
However, this approach is rarely used because it requires 3 to 4 months to produce results.
Indeed, only 7% of all MDR-TB cases are detected globally [1]. Hence, the deficiency in tools
for rapid DST is associated with inadequate treatment regimens, which tragically increase
transmission and spread of drug resistant TB, especially in HIV-infected individuals [38]. This
alarming situation stimulated the development of a great number of rapid culture- and
molecular-based methods that are currently being evaluated in TB diagnosis laboratories. The
Nitrate Reductase Assay (NRA) is based on detection of nitrate reduction into nitrite by Mtb
organisms capable of growth in the presence of the test antibiotic [39]. Whereas the Microscopic
Observation of Drug Susceptibility (MODS) uses inverted microscope to detect the formation
of cord-like structure by Mtb isolates resistant to the test drug [40]. The commercial Mycobac‐
terium Growth Indicator Tube 960 (MGIT 960) is a drug-containing culture system based on
the fluorescence detection of resistant bacteria [41]. The Genotype MTBDRplus is a molecular
line-probe assay that detects simultaneously mutations in the rpoB gene that confers resistance
to RMP as well as mutations in the katG gene and the inhA promoter, which are associated
with resistance to INH [42]. The Alamar blue and resazurin assays are liquid-based colori‐
metric tests [43]; a color change in wells containing drug-exposed bacteria reflects resistance.
The MTT assay relays on the ability of drug-resistant (viable) bacteria to cleave the tetrazolium
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rings of MTT, which produces a violet-purple color [44]. Many of these assays gave excellent
detection of MDR-TB, within a significantly shorter time frame when compared to conven‐
tional culturing methods (Table 1).
The effective implementation of these rapid diagnostic tests for TB and drug resistance will
increase the proportion of patients promptly placed on appropriate therapy, and therefore will
improve substantially management and control of TB disease globally. However a major
limitation to the use of these rapid tests is their affordability and the availability of equipped
laboratories in resource-constrained countries, which unfortunately tend to have the highest
burden of MDR-TB cases. Thus, global initiatives are needed to make new diagnostics
accessible to low-income countries.
MTBDRplus MODS NRA AB Resazurin MTT MGIT 960 LJPM
Average time
to results, days 2 7 7 8 8 8 9 30
Results within
8 days, % 100 90 77 87 87 74 42 -
Results within
10 days, % 100 100 100 100 97 87 81 -
MODS = microscopic observation drug susceptibility; NRA = nitrate reductase assay; AB =Alamar Bbue ; MTT = 3-[4,5-
dimethyl- thiazol-2-yl)-2,5-diphenyltetrazolium bromide; MGIT = Mycobacterium Growth Indicator Tube; LJPM =
Löwenstein-Jensen proportion method.
Table 1. Time to results and percentage of results obtained within 8 and 10 days. Reprinted from Ref. 45 with
permission of the International Union Against Tuberculosis and Lung Disease. Copyright © The Union.
5. Treatment of drug-resistant TB
The emergence of MDR- and XDR-TB has shattered the initial optimism that DOTS based
programmes would progressively eliminate TB. MDR TB is defined as resistance to at least the
two most potent first-line TB drugs—ie, INH and RMP [46,47]. XDR TB strains are resistant to
INH or RMP, any fluoroquinolone, and at least one of three second-line injectable drugs—ie,
capreomycin, kanamycin, and amikacin [46,47]. In order to control the spread of drug resist‐
ant TB, the WHO extended the DOTS programme in 1998 to include the treatment of MDR-TB
(called "DOTS-Plus") [48]. Implementation of DOTS-Plus requires the capacity to perform drug-
susceptibility testing and the availability of second-line agents, in addition to all the require‐
ments for DOTS. Clinical pilot experiences from the past few years showed that high cure rates
of drug resistant TB are achieved in settings where DOTS-Plus has been established [49-51].
Resistance to INH is the most common form of TB drug resistance reported, either in isolation
or in combination with other drugs [13]. INH monoresistant TB is relatively easy to treat with
SCC treatment. Up to 98% cure and less than 5% relapse can be achieved when all four drugs
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INH, RMP, PZA and EMB are used during the 6-month treatment period [52]. RMP-resistant
TB often carries a much more ominous prognosis, as the outcome of SCC treatment is poor in
terms of both disease status at the end of the treatment and relapse [13]. Moreover, RMP
monoresistance in Mtb is rare and usually reflects resistance to INH as well, i.e., MDR-TB [53].
In fact, SCC cures less than 60% of MDR-TB, with a recurrence rate of about 28% among patient
with apparent success [38,54].
The current recommendation for individualized treatment regimens is a combination of at
least four drugs to which the Mtb isolate is likely to be susceptible [55]. Drugs are chosen with
a stepwise selection process through 5 groups of TB drugs (Table 2) on the basis of efficacy
and safety [55]. More than 5 drugs can be used if the sensitivity to a given drug is unclear or
if the regimen contains few bactericidal drugs. The duration of the intensive phase of treatment
(when an injectable drug is given) should be at least 6 months (or 4 months after culture
conversion). The continuation phase (without the injectable drug) should last until 18 months
after culture conversion [55].
Although the effectiveness and feasibility of MDR-TB management in resource-limited
settings have been demonstrated, less than 2% of all estimated MDR-TB patients currently
receive appropriate treatment [5]. Thus, the growing MDR-TB epidemic globally requires
moving beyond the pilot project stage in order to scale up DOTS-plus based TB management
as a routine component of national TB control programmes. However, there are potential
difficulties with implementing DOTS-Plus in low-income countries as it can absorb a large part
of resources dedicated to existing DOTS programmes, and subsequently decrease the overall
standard of care [56]. Note that the emergence of drug resistant TB in these countries is actually
the result of limited resources to implement the simple DOTS programme.
A major barrier to the management of drug resistant TB in low-income countries is the prohibi‐
tive price of second-line drugs. Therefore in an attempt to address this issue, in 2000, the WHO
and its partners established the Green Light Committee (GLC) initiative to facilitate access to
quality-assured second-line TB drugs at reduced prices [57,58]. Evaluation of the first GLC-
endorsed pilot projects of MDR-TB management in five resource-limited countries showed
treatment success rates of 59%–83% [59]. During 2012, the number of patients with MDR-TB
approved for treatment by the GLC Committee was only 42,033 with 13,000 actually starting
treatment. It is clear that these numbers remain small compared to the estimated annual incidence
(440,000 cases) of MDR-TB [1]. Therefore, substantial funding through public-private partner‐
ships is desperately needed to scale up the availability of second line drugs.
Other than the price of second-line drugs, frequent adverse events and the long duration of
the regimen further compromise adherence to TB treatment, even in the most advanced
industrialized countries. These drawbacks have resulted in resurgence in research efforts
during last decade to develop new TB drugs. In recent years, a number of new drug candidates
with novel modes of action and excellent activity against Mtb have entered clinical trials [60].
OPC-67683 (nitro-dihydro-imidazooxazole) and diarylquinoline TMC207 are the most
promising of these new drugs since both are highly active against drug-resistant and suscep‐
tible Mtb strains and possess excellent sterilizing activity [61]. These and other drugs under
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development give hope that a safe and effective TB regimen of shorter duration will be
available within the next few years.
6. Adverse drug reactions to second line TB drugs
The treatment of MDR-TB is a challenging issue due to the adverse events associated with
long-term exposure (18 to 24 months) to second line drugs, all in great contrast to the short
treatment period of drug sensitive TB. Adverse events significantly influence treatment
TB drug group Daily dose
Group one: first-line oral TB drugs (use all possible drugs)
Isoniazid
Rifampicin
Ethambutol
Pyrazinamide
5 mg/kg
10 mg/kg
15–25 mg/kg
30 mg/kg
Group two: fluoroquinolones (use only one, because they share genetic targets)
Ofloxacin
Levofloxacin
Moxifloxacin
15 mg/kg
15 mg/kg
7.5–10 mg/kg
Group three: injectable TB drugs (use only one, because they share very similar genetic targets)
Streptomycin
Kanamycin
Amikacin
Capreomycin
15 mg/kg
15 mg/kg
15 mg/kg
15 mg/kg
Group four: less-effective second-line TB drugs (use all possible drugs if necessary)
Ethionamide/Prothionamide
Cycloserine/Terizidone
P-aminosalicylic acid (acid salt)
15 mg/kg
15 mg/kg
150 mg/kg
Group five: less-effective drugs or drugs on which clinical data are sparse (use all necessary drugs if there are less ily
than four from the other groups)
Clofazimine
Amoxicillin with clavulanate (every 12 h)
Linezolid
Imipenem (every 6 h)
Clarithromycin (every 12 h)
High-dose isoniazid
Thioacetazone
100 mg
875/125 mg
600 mg
500–1000 mg
500 mg
10–15 mg/kg
150 mg
Table 2. Categories of TB drugs. Reprinted from Ref. 55 with permission of the International Union Against
Tuberculosis and Lung Disease. Copyright © The Union.
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outcome and patient compliance, leading to acquisition of more resistance and spread of drug-
resistant strains. Initial evidence of the prevalence of adverse events associated with the use
of second-line drugs was deducted from observation of patients enrolled in five DOTS-Plus
sites: Estonia, Latvia, Peru, the Philippines and the Russian Federation. The data collected from
these sites showed that among 818 patients enrolled on MDR-TB 30% required removal of
suspected drugs from the regimen due to adverse events [62] and Table 3.
Adverse events can be distinguished as major or minor and may not be consistently found
among all patients treated for MDR-TB [39]. The major adverse events associated with second
line drugs include auditory toxicity (ototoxicity) and neurologic side effects [63].
Ototoxicity causes damage to the outer hair cells in the cochlea and vestibular labyrinth leading
to permanent hearing loss. Ototoxic hearing loss is common in patients treated with amino‐
glycosides (Streptomycin, Kanamycin and Amikacin). A prospective cohort study of the
incidence of ototoxicity in MDR-TB individuals (with normal hearing) showed that 57% of
aminoglycoside-treated patients developed high-frequency of hearing loss [64]. The same
study showed that HIV-positive patients (70%) were more likely to develop hearing loss than
HIV-negative patients (42%). Susceptibility to hearing loss increases further in patients bearing
mutations in mitochondrial genes [65]. Numerous mutations linked to susceptibility to
ototoxicity have been identified in the mitochondrial MT-RNR1 gene that encodes the human
12S rRNA ribosomal subunit. In particular, the A1555G mutation causes increased binding of
aminoglycosides to the 12S rRNA ribosomal subunit [66], which results in the disruption of
mitochondrial protein synthesis and death of the cell. In this regard, a recent study in South
Africa detected A1555G mutation in a significant proportion of the population (0.9% of Black
and 1.1% of Afrikaner), indicative of high proportion of individuals genetically predisposed
to developing aminoglycoside-induced hearing loss. It is unfortunate that the widespread and
poorly controlled use of aminoglycosides will lead to many individuals suffering from
permanent deafness. Auditory monitoring should be an integral part of the care programme
of MDR-TB patients, particularly in countries where aminoglycosides are still commonly used.
In addition, identification of patients who are genetically predisposed will significantly reduce
the risk of developing ototoxicity.
Patients with neurologic side effects (depression, psychosis and suicidal tendencies) have less
favorable outcome and increased risk of death. Cycloserine is the most significant TB drug
associated with central nervous system (CNS) toxicity. Cycloserine is used as second line drug
in TB treatment based of its structural analogy to D-alanine. Cycloserine competitively inhibits
two necessary enzymes (alanine racemase and alanine ligase) that incorporate alanine into an
alanyl-alanine dipeptide, an essential component of the mycobacterial cell wall [67]. Early
studies revealed that neurological and psychiatric manifestations are present in as many as
33% of patients treated with cycloserine [68]. The principal side effects associated with
cycloserine therapy are convulsions, exacerbations of bipolar states and multiple neurological
symptoms including excitation, dizziness, headaches, insomnia and anxiety [69]. Cycloserine-
mediated neurologic side effects are exacerbated even more when used in combination with
isoniazid [70]. These variable psychotropic responses are related to cycloserine action as an
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agonist of the neuronal NMDA (N-methyl-D-aspartate) receptor for glutamate [71], which is
a major excitatory neurotransmitter in the mammalian CNS [72]. The most dramatic effect of
cycloserine reported so far is the suicide of 2 patients during the postoperative antibiotic
treatment course following pulmonary resection [73]. Because of its neurological toxicities,
cycloserine was prevented very early from being part of first line TB drugs but was recently
reintroduced as one of the cornerstones of treatment for MDR- and XDR-TB [46]. Although co-
administration of pyridoxine (vitamin B6) with cycloserine can reduce partially the neurolog‐
ical side effects, the later should be prescribed after psychiatric evaluation for patients with
apparent convulsions and agitation [55]. Some clinicians favor terizidone (two cycloserine
molecules combined) as they found the side effects associated with it are less severe and more
manageable [55]. However, given the little evidence demonstrating safety and efficacy of
terizidone, it should be used with caution in TB patients intolerant to cycloserine.
Although adverse events associated with second-line drugs are a major obstacle in the
management of MDR-TB, compared with first line treatment, DOTS-Plus programmes have
achieved cure rates of greater than 70% even in resource-poor settings [74,75]. In general, the
Table 3. Frequency of adverse events and suspected agents among 818 patients receiving MDR-TB treatment.PAS:
para-aminosalicyclic acid; TM: thioamides; FQ: fluoroquinolones; CS: cycloserine; AG: aminoglycosides; CM:
capreomycin.. Reprinted from Ref. 62 with permission of the International Union Against Tuberculosis and Lung
Disease. Copyright © The Union.
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main adverse effects of anti-TB drugs occur during the first two to three weeks of treatment.
If they are recognized in time and managed properly, high rates of treatment completion and
cure can be achieved. Proper monitoring should include patient education, clinical examina‐
tion and appropriate laboratory tests. Special training for staff on the various adverse events
associated with second line drugs is essential for successful management. In particular, staff
should consider altering dosages when appropriate, supplementary drugs to treat adverse
events and replacement of drugs when toxicity cannot be managed.
7. Management approaches for the contacts of MDR TB patients
MDR-TB and XDR-TB cases are currently on the increase and it is expected that the number
of their contacts will also increase, especially in densely populated area. Therefore, identifica‐
tion and proper management of these contacts are major components of drug resistant TB
containment. In this regard, WHO recommend the identification of all close contacts of MDR-
TB cases through contact tracing and their evaluation for TB infection.
A contact is defined as an individual who has a risk of acquiring TB because it has been exposed
to Mtb by sharing air space with a person with infectious TB (the source case). The index case
(a person with suspected or confirmed TB disease) is defined as the initial case of TB for a
contact investigation [76]. He is not necessarily identical with the source case [76]. Many
guidance documents focus on the source case and not the index case, as it is the source case
who will have exposed the contacts, not necessarily the index case. Close contacts are those
people sharing common habitation rooms with the source case. This can also include individ‐
uals with evidence of prolonged and frequent exposure to a source case in the workplace,
school, prison, hospital ward, or social settings [77]. Contact tracing is defined as the systematic
finding of contacts of patients with infectious TB disease [77]. The tracing helps identifying
individuals who are particularly at high risk, such as individuals with HIV infection, young
children and elderly.
The management of contacts of drug-resistant TB patients, in term of preventive chemoprophy‐
laxis, remains a complex issue with a significant ethical dimension. In case of drug-susceptible
TB, the provision of preventive INH therapy to suspect LTBI individuals is effective at reduc‐
ing the risk of developing disease among infected contacts [10]. In theory, such a preventive
approach should also work for LTBI individuals exposed to MDR and XDR Mtb strains.
Unfortunately, health care providers cannot predict with certainty the susceptibility pattern of
a contact’s isolate from the source case’s isolate. Indeed, many divergent drug susceptibility test
profiles in source-contact pairs have been reported [78,79], due either to infection of the contact
by another source case or to infection before the source case acquires resistance. Such a scenar‐
io likely occurs in high-burden TB areas where different drug resistant strains may circulate in
homes, schools, and work places. Therefore, the lack of effective drugs with acceptable adverse-
event profile in an otherwise healthy individual is a prominent barrier to the treatment of drug
resistant TB contacts. Indeed, if, to some extent, the occurrence of toxicity is accepted by MDR-
TB patients (since the alternative is high risk of death), convincing healthy contacts to cope with
adverse-events during preventive therapy in is fundamentally different.
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Given the lack of clear evidence in support of preventive therapy, the WHO does not recom‐
mend universal use of second-line drugs for chemoprophylaxis in MDR-TB contacts. Current
guidance for the management of drug resistant TB contacts are largely based on expert
opinions, which do not reject nor support provision of preventive therapy with the currently
available drugs. In this context a guidance document presenting the most up-to-date evidence
and expert opinion regarding the management of contacts of MDR- and XDR-TB patients has
been recently proposed (March 2012) by the European Centre for Disease Prevention and
Control (ECDC) [76]. Box 1 summarizes key recommendations provided by ECDC document.
Which factors should be evaluated to decide whether to provide preventive therapy to MDR TB contacts
considered to have LTBI?
When evaluating an MDR TB contact and deciding between the two options (to provide preventive therapy and/or
careful clinical observation and information), an overall individual risk assessment should be conducted, taking into
consideration the following: the MDR TB contact’s risk for progression to TB disease; the drug susceptibility pattern of
the source case of infection; and the contact’s risk for adverse drug events if initiating preventive therapy.
Are there any specific risk groups to whom special attention should be paid?
Children below the age of five years and immunocompromised persons in close contact with MDR TB patients and
considered to have LTBI are at particular risk of progressing to TB disease. These risk groups might benefit from
preventive therapy. The preventive therapy may be interrupted if, based on further examination, infection is found to
be unlikely.
Persons over five years of age in close contact with MDR TB patients and considered to have LTBI could also be
considered for preventive therapy if the individual risk assessment indicates this course of action.
If the decision is made to put an individual on preventive therapy, the selection of the drugs should be based on:
the drug susceptibility pattern of the source case’s likely infecting strain;
local patterns of drug resistance;
the potential adverse events in individual patients, taking into account age and other risk factors;
the selection of single or multiple drugs and the duration of treatment will depend on the availability of drugs with
bactericidal activity for the particular infecting strain; alternatively, the decision can follow national guidelines.
Which arrangements should be in place if preventive therapy is considered?
If preventive therapy is considered by the expert physician or other healthcare provider, national legislation should
ensure that the treatment costs for the patient are covered.
If preventive therapy is considered to be relevant for a particular individual, careful clinical monitoring and follow-up is
essential for the detection of drug-adverse events and signs of TB disease if the preventive therapy is not effective.
Specific opinions for XDR TB contacts
As the currently available treatment options are very limited for XDR TB, it is likely that the risks of preventive therapy
outweigh the benefits for contacts of XDR TB patients. Thus, the option to inform and observe the contacts will be
preferable, given the currently available drugs and evidence.
How should health authorities conduct follow-ups for MDR TB and XDR TB contacts suspected to have LTBI?
All MDR TB and XDR TB contacts considered to have LTBI who, after a comprehensive individual risk assessment, are
not given preventive therapy should be followed-up by careful clinical observation.
Follow-ups should be performed according to existing national guidelines.
All persons in contact with MDR TB or XDR TB (after exclusion of TB disease) should be informed about the risks and
symptoms, carefully observed, and provided with easy access to a specialized TB clinic in case of symptoms between
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assessments. No specific time period for follow-up or periodicity of clinical assessments is recommended, but regular
systematic, clinical observation is essential for the early detection of TB disease.
Individuals repeatedly in contact with infectious MDR TB or XDR TB cases (e.g. healthcare workers) should be re-
examined periodically.
Box 1. ECDC expert opinions regarding preventive therapy of MDR- and XDR-TB contacts.
Studies conducted so far on the benefits and adverse events of preventive therapy are not
conclusive in term of optimal treatment and duration for preventive treatment of MDR-TB
contacts [80]. Therefore, well-designed randomized clinical trials for preventive therapy are
urgently needed in settings where MDR-TB therapy and a strong national programme
infrastructure are already in place. Further research is also needed to define the most effective
contact-tracing procedures for contacts and the most effective follow-up procedures in
healthcare workers constantly exposed to drug resistant TB. In addition, specific management
approaches need to be established for children below the age of five years, children with HIV
infection, immunocompromised individuals, pregnant women, and the elderly. Finally,
whether MDR Mtb strains are more or less infectious and/or transmissible than drug-suscep‐
tible strains need to be clarified.
8. Compliance issues from patients and health care providers
The treatment for MDR-TB is long and complex and relies on a handful of antibiotics with
uncertain efficacy. The WHO has launched an 8-point plan to ensure optimal management of
XDR-TB patients with currently available drugs (Box 2). However, guidelines do not always
translate easily into real world practice. In addition to directly observed treatment, what support
can be offered to convince a patient to continue painful treatment? And how should patients
who have exhausted all treatment options with existing second-line drugs be cared for?
1. Strengthen quality of basic TB and HIV/AIDS control
2. Scale up programmatic management of MDR-TB and XDR-TB
3. Strengthen laboratory services
4. Expand MDR-TB and XDR-TB surveillance
5. Develop and implement infection control measures
6. Strengthen advocacy, communication and social mobilization
7. Pursue resource mobilization at all levels
8. Promote research and development of new tools
Box 2. WHO 8-point plan
In many cases, MDR-TB treatment results in poor compliance with subsequent development
of further drug resistance (i.e. XDR-TB), which leaves infected patients, namely HIV positive
individuals, virtually untreatable using currently available drugs. The WHO defines a
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defaulter as being off drugs for more than 8 weeks after completing at least one month of
treatment [81]. It is an operational definition to guide physicians in the decision of using a
retreatment or second line regimen if the patient comes back to the health facility after
defaulting. However it is imperative that health providers understand predictive factors for
treatment default so that they can implement additional measures to target the population at
risk. In this context, a recent review (2010) assessed TB treatment compliance and the factors
predictive for poor adherence based on the analysis of 4 studies performed in Sub-Saharan
Africa in the last 10 years [82]. The review revealed a high proportion of patients defaulting,
which varied between 11.3% and 29.6%. Defaulting appears to be associated with many factors
such as distance from the hospital, not being on the first course of TB medications, lack of
repeated smears, drug-associated side effects, transportation difficulties, absence of family
support and poor knowledge about TB disease and its treatment. Thus it is unfortunate that
health care institutions continue to blame vulnerable and powerless patients who are unable,
for this multitude of reasons, to comply with the treatment. Since distance from health care
centers is a major factor, national programmes should at least consider making drugs more
widely available, by either providing TB treatment in smaller health centers, or organizing
mobile TB clinics, especially in rural areas.
It is time to admit that TB disease is not a ‘patient problem’ by default but rather a social and
community responsibility that requires close cooperation and collaboration at all levels of the
health care system. Forcing a patient to continue an ineffective, toxic regimen that results in
uncertain outcome also raises an ethical issue yet to be resolved. Ereqat and colleagues report‐
ed a recent case of a MDR-TB patient who withdrew from treatment after 2 years while still
sputum-positive [83]. Due to persistent efforts to force compliance, the patient disappeared
carrying with him the potential to infect all people with whom he has contact. The authors suggest
consulting with legal practitioners about the legality of enforced treatment and how patients
who refuse or interrupt treatment can be managed to protect them and their potential con‐
tacts. It is obvious that in the absence of alternative treatment, this approach might end up with
a response to TB without medication (i.e incarceration). For this type of recalcitrant patients,
other TB specialists [84,85] propose directing efforts towards exploring possible regimens with
better chances of cure and securing an appropriate living environment. Indeed, the threat of
incarceration will just encourage patients to disappear and propagate the disease. Providing
supportive accommodation with access to counseling and palliative care, when required, should
reduce the risk of transmission to others [84]. Overall, until newer drugs become available,
management that balances the risk of disease spread with individual human rights is likely to
be more humane and less costly to health services compared with involuntary detention [85]. In
this context, Upshur and Colleagues propose a list of additional considerations to the manage‐
ment of drug resistant TB as moral correlates to the current WHO 8-point plan (Box 3).
A paramount issue in TB management is that in many countries with limited resources most
of the healthcare is provided by the private sector where the number of qualified medical
personnel to prevent and treat drug resistant TB remains very limited. In this regard, the World
Medical Association (WMA, http://www.wma.net) revealed that many doctors are no longer
being taught to diagnose and treat TB. Thus, private physicians make frequent errors in dealing
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with TB cases. They prescribe too few drugs or the wrong drugs, give inadequate doses of
drugs, or prescribe an inadequate duration of treatment [86]. The standardized method of
determining cure is based on bacteriologic laboratory testing for the growth of Mtb on culture
media. However many health care providers rely on clinical observation to determine
treatment outcome [87], either because of shortages in equipment and adequate infrastructure
or because they trust their own observation above test results. Such mismanagement is a major
cause of acquired drug resistance and treatment failure. On the other hand, on many occasions
lung cancer was misdiagnosed and treated as sputum negative TB, a medical error due to high
TB prevalence and radiological similarities [88].
It is therefore important that healthcare personnel at the forefront in the fight against TB
acquire appropriate and state-of-the art training on TB management. In this regards, the WMA
launched in its website a new online refresher course for care providers in many languages.
The course provides basic clinical care information for TB including the latest diagnostics,
treatment and information about multidrug-resistant TB. It also provides information on how
to ensure patient adherence and infection control and includes many aspects of TB care and
management. Dr. Julia Seyer, medical adviser at the WMA, said: ‘When we started an online
MDR-TB training course in 2006, we discovered that many physicians were missing the most
basic knowledge about normal TB’.
In summary, both the lack of patient adherence to treatment and deficiencies in programme
managements are compromising the effectiveness of MDR TB treatment and the interaction
of these two issues raises further the barrier to achieving efficient TB control. From the various
opinions on the issue of non-compliance it can be concluded that:
• Addressing therapy-related adverse events should contribute positively in improving
patient’s compliance. Therefore, potential adverse effects must be carefully evaluated when
designing the therapy plan. Alternative plans should be discussed with the patients to
minimize the possibility of therapeutic barriers.
• Healthcare system quality is significantly related to compliance. Long waiting times and
unhappy experiences during clinic visits are frequent complains from TB patients. A
healthcare system that considers patient satisfaction would enhance patient adherence to
TB treatment.
• Compliance is also affected by the characteristics of TB disease. While non-adherence is not
a major issue when treating short duration infections, this is not the case for TB, a chronic
1. Adherence research
2. Building the evidence-base for infection control practices
3. Supporting communities
4. Enhancing public health response while addressing the social determinants of health
5. Embracing palliative care
6. Advocacy for research
Box 3. Additional considerations to the WHO 8-point plan
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disease by definition. Therefore, special effort should be made to explain the nature of the
disease with a particular focus on the asymptomatic stage of TB.
• Healthcare expenditures are a very important factor that affects compliance. TB patients
often feel that the cost of long-term treatment would be a financial burden, which definitely
threatens therapy compliance. Therefore, health care personnel should discuss the patient’s
resources and help identifying sources that might provide financial assistance to low-
income patients.
Overall providing care centered on patient needs and expectations is a key component for the
success of TB control programmes.
9. Programmatic management of drug resistant TB
Policies, strategies, protocols and guidelines for TB management are well explained and
articulated on the paper. However, their implementation in resource-limited sittings remains
challenging due to weak case finding strategies, unclear patient tracing mechanisms (espe‐
cially defaulters), a lack of MDR-TB rapid diagnostic tools, absence of childhood TB case
finding approaches and inadequate patient support services. Furthermore, specialized drug
resistant TB services are limited to locations that often exclude many patients living in remote
areas from receiving adequate health care. Recording systems, mainly paper-based, are time
consuming for health care providers, and therefore reduces time for quality care. Addressing
these many challenges requires collaboration from different components of national TB control
programmes. These components include case detection, treatment, prevention, surveillance,
and adequate monitoring/evaluation of the programme’s performance. Such objectives are the
backbone of DOTS-Plus management programme introduced by the WHO in 1998 [48]. Many
DOTS-plus pilot projects provided evidence base for this strategy in the management of drug
resistant TB [59,89,90]. Based on the success of pilot projects, the WHO issued in 2006 guide‐
lines for what is now called programmatic management of drug-resistant TB (PMDT), which
were recently updated with extra focus on the detection and treatment of drug-resistant TB in
resources limited settings [91]. Priority topics identified in the new WHO document are:
• Case-finding through use of rapid molecular tests; investigation of contacts and other high-
risk groups;
• Regimens for MDR-TB and their duration in HIV-positive and HIV-negative patients;
• Monitoring during treatment;
• Models of care.
PMDT is currently highly supported by funding for MDR-TB treatment, which has dramati‐
cally increased in the past few years. Multi-billion dollar funds are now available through
governments and donors, including the Global Fund to Fight AIDS, Tuberculosis and Malaria,
UNITAID and the GLC committee [90]. Such fund was essential to demonstrate the feasibility
and effectiveness of PMDT in many resource-limited settings, where it is needed most [92].
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The current status of MDR-TB epidemic requires urgent moving of PMDT beyond this pilot
project stage in order to respond to the call of Stop TB for the treatment of 1.6 million MDR-
TB patients in the near future [93].
Although the last WHO document on TB control provides comprehensive guidelines for good
PMDT, The WHO recognizes that many crucial management issues remain to be addressed.
Thus, during the development of the recent PMDT document, a review published in 2008 [92]
revealed some important gaps in knowledge that need to be addressed in order to optimize
PMDT:
• Lack of high quality evidence from randomized controlled trials for optimizing treatment
regimens in patients with MDR-TB, including the best combination of drugs and treatment
duration;
• Very limited information about treatment and management of pediatric MDR-TB;
• Identification of the most effective chemoprophylaxis for contacts of MDR-TB cases;
• The therapy for symptomatic relief from adverse reactions linked to second-line TB drugs.
It is also important to note that social stigma and discrimination are still major obstacles for access
to TB care services in many countries [94,95]. Similarly, financial issues and geographical
accessibility is also a barrier for the continuation of treatment [96,97]. Misconceptions about TB
are highly prevalent, which discourages seeking help in time or encourage those with TB to seek
help from traditional healers [98]. Therefore national TB programmes must also include specific
strategies to combat these issues in order to optimize the implementation of good PMDT.
Diversity in the epidemiology of MDR-TB poses a challenge for its management in various
settings [99]. Ideally, TB management approaches need to be adapted to each particular setting.
However it is possible to build a minimal package that could be adapted to specific countries
wishing to implement proper TB management approaches. Accordingly, in 2003 a Stop TB
Working Group on DOTS-Plus for MDR-TB identified key research questions to be answered
in order to scale up the management of all forms of drug-resistant TB and to maximize its
public health impact [99]. The working group felt that evidence is needed to address the
following questions:
• How can regimens be selected (either at the programme or at the individual patient level)
based on standardized and reproducible DST that adequately reflects in vivo responsiveness
to treatment?
• How can setting specific treatment strategies be optimized with respect to effectiveness,
complexity (dosing, eligibility, duration, and monitoring of outcome and side effects),
safety, adherence, and affordability?
• What is the minimum infrastructure needed to scale-up PMDT, in terms of:
◦ laboratory and treatment provision
◦ efficient and equitable patient selection
◦ prevention of transmission to other patients and health care workers
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• How should infected contacts of DR-TB patients be managed?
Ensuring that these research questions are addressed is the responsibility of all parties involved
in the management of MDR-TB. If adequately addressed, they will generate a solid evidence-
base to support existing WHO guidelines.
The integration of PMDT into existing TB control programmes beyond the limited pilot project
phase has become a critical emergency in order to respond to the increasing spread of MDR/
XDR-TB worldwide. However, analysis of current WHO strategies by many experts in the field
of TB management [100] suggest that successful PMDT will still require:
• New and improved tools for drug resistance testing;
• Clinical trials to test the efficacy and effectiveness of simplified and shorter second-line
treatment regimens as well as of candidate second-line drugs;
• New and improved strategies for identifying patients with drug-resistant disease, promot‐
ing treatment adherence, and improving infection control;
• Better epidemiological data to explain geographic variations in occurrence of drug resist‐
ance and to identify the greatest contributors to development of drug resistance in specific
settings;
• Clinical trials to test the efficacy and effectiveness of new regimens for prophylactic
treatment of contacts of patients with DR-TB.
10. Patient centered care approach
Acquiring adequate care for TB is becoming increasingly complex and costly when patients
are infected with drug resistant Mtb. This problem is further amplified when patient access to
health care centers is limited and adequate patient-clinician relationships are absent. To
address this issue Stop TB included patient centered approach as one of its important under‐
lying principles. It insists on respect for patients right as individuals and as partners in TB care
and control. Therefore what are usually characterized as ‘patient problems’ need to be
reconfigured into solidarity with patients and programmatic challenges. Patient-centeredness
can be traced back to the adoption of the right to health as part of the International Human
right declaration in 1948 [101], but it is only in the 1990s, as result of the community reaction
to the AIDS epidemic, that its importance has been perceived. Since then, the rise in prevalence
of all forms of TB in HIV individuals has become one of the major stimulating factors for
implementation of patient-centered approaches in TB care.
Promoting patient-centered case management involves assessing each TB patient's needs and
identifying a treatment plan that ensures the completion of therapy. Policies and guidelines
for patient-centered approaches are currently widely distributed. Unfortunately, their
application in the field is progressing very slowly. Applying a patient-centered approach takes
time and requires effort at many levels. It is a new way of thinking, teaching, providing care,
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prevention and communication [102]. Therefore, many countries will continue to experience
substantial difficulties in treating drug resistant TB patients at high risk of defaulting.
A systematic review of factors that contribute to non-adherence [103] indicate that many social
and economic barriers prevent patients from successfully completing their treatment. A wide
range of interacting factors impact on the patient behavior, which is subject to changes during
the course of treatment. According to Doctor Without Borders [104], one of the major chal‐
lenges faced by drug resistant TB patients is the long and arduous treatment period, which
can involve large numbers of tablets each day, as well as injectables, both expensive and not
always easily available or accessible. Low-income patients living in remote area often struggle
to reach specialized TB clinics, in particular when the harsh winter weather affect severely the
country’s road network and compromises the transportation system. Therefore, in the absence
of efficient patient-centered approaches, it is almost impossible to convince patients to continue
this forceful effort every day for up to two years.
In the Russian Federation, the proportion of MDR-TB patients defaulting from treatment has
increased from 12% in 2001 to almost 30% in 2004 [105], despite the expansion of the DOTS
programme to include the treatment of drug resistant TB in 2000. This failure to control drug
resistant TB was mainly attributed to the absence of patient-centered strategies adapted to
many risk factors for non-adherence such as poverty, unemployment, homelessness, alcohol‐
ism, drug abuse and mental illness, to name a few [105]. In response to the alarming proportion
of defaulters, a novel patient-centered TB treatment delivery programme (Sputnik) was
introduced in Tomsk City [106]. Sputnik care providers accompanied patients through
treatment by remaining responsible for patients from the time of enrollment in the programme
until the end of treatment (Box 4). The programme paid a particular attention to care giving.
In addition to clinical preparation, nurses received a comprehensive training on how to care
for patients facing a myriad of biosocial challenges. Indeed, a review of the emotional support
that nurses provide to patients living with MTR-TB [107] concluded that nursing of TB patients
could be improved with an integrated approach where the nurses are responsible for treating
not only the patient, but also ambient factors that affect health, such as family and community.
A high nurse-to patient ratio (2:15),
More staff time per patient to facilitate bonding and defaulter searching
Provision of portable phones to nurses, which increases flexibility
Easier access to specialists
Expanded social and psychological support, which included clothing and assistance with
procuring documentation required to access social services
Box 4. Sputnik programme package
The application of the Sputnik programme led to a mean adherence of 79.0% and a cure rate
of 71.1%, indicating that adapted patient-centered approaches contributed significantly to
improving TB patient adherence.
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In 1998, the Centers for Disease Control and Prevention (CDC) and the Institute of Medicine
of the National Academy of Sciences conducted a study to determine if TB eradication in the
United State was feasible. The resulting report “Ending Neglect: The Elimination of Tuberculosis
in the United States” concluded that TB elimination would require “aggressive and decisive
action beyond what was in effect.” One of the top objectives of the new CDC plan is to ensure
that patient-centered case management and monitoring of treatment outcomes are the
standard of care for all TB patients [108]. In particular, the CDC guidelines recommend all
patients with active TB must be tested for HIV infection and that all patients double infected
with Mtb and HIV infection must be appropriately and adequately treated. To ensure adher‐
ence to treatment, the CDC recommend the inclusion of multiple enablers (e.g., transportation
vouchers and housing for the homeless) and incentives that will motivate the patient (e.g., food
coupons), and other treatment enhancers such as alternative treatment delivery sites, and
strategies to overcome social and cultural barriers.
Addressing social and economic barriers definitely increases patient access to adequate TB
care. However, health education would also strengthen patient-centered approaches. Under‐
standing an illness and how it affects ones life, as well as available treatment options, are
necessary for a patient and community to take an active role in TB management. With input
from community health professionals from several countries, a literacy tool kit “Within Our
Reach: A TB Literacy Toolkit” was developed in 2009 for health educators, outreach workers,
counselors, and supervisors who provide services to TB patients [109] and (Box 5).
Increasing knowledge about TB, the link between TB and HIV, TB treatment, and TB
transmission
Raising awareness that TB is a serious but treatable disease
Giving patients confidence that they can complete TB treatment and be cured
Educating caregivers and families about how to support TB patients
Reducing stigma attached to TB and HIV
Box 5. Supporting objectives of the TB Literacy Toolkit
The tools are designed to educate TB and HIV patients, their caregivers, and their communities
about TB and what it takes to complete a full course of TB treatment. The kit developers suggest
that individual sessions should be conducted with flipcharts between the health provider and
patient, and videos should be played in a waiting area or during community education events.
Patient-centeredness has become a central approach towards realizing universal access for all
patients to efficient TB care. However scaling up this approach is progressing slowly in high
TB-burden countries and is mainly challenged by the socio-economic determinants of knowl‐
edge and attitudes about TB among health care providers and the general population.
Therefore optimal patient-centeredness approach requires collaborative efforts between all
organizations serving TB patients to ensure that health care providers, policy makers, com‐
munity leaders and the public are knowledgeable about TB disease.
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11. Drug resistant TB infection (tansmission) in the community and
hospitals
TB is a highly contagious disease, acquired mainly through inhalation of airborne aerosols.
Infection can occur by inhaling as few as 5-10 living bacteria. People with active TB infection
spread the bacterium not only by coughing and sneezing but also by spitting, speaking, singing
or laughing. The infectiousness of a TB patient is directly related to the number of droplet
nuclei carrying Mtb that are expelled into the air. These droplets rapidly evaporated to form
tiny particle nuclei, which could remain airborne for several days [110]. Given this mode of
propagation, a person with active TB can spread the germs to up to 15 people in a year, if left
untreated [4]. Therefore the process of TB spread also needs to be controlled in order to
successfully combat the TB epidemic. In this regards, Nardell recommend the term “trans‐
mission control of TB” instead of “infection control of TB”, since a third of the world’s
population is already infected with TB, a situation that appear to be stationary [111].
Because MDR strains carry mutations in major metabolic activities, in particular INH resistant
strains lacking catalase activity [112], some researchers have suggested that they may be less
virulent and less transmissible [113]. Contrasting with this hypothesis, the epidemic that
occurred in New York City in the 1990s [114,115], which affected mainly HIV-infected persons,
proved that MDR strains are highly virulent and transmissible. Current data on MDR TB
prevalence in Africa, Eastern Europe and Asia [116] provides further evidence of this phe‐
nomenon. Drug resistant TB can be transmitted in virtually any setting but healthcare settings,
correctional institutions and homeless shelters have an increased risk of transmission. The level
of drug resistance TB in hospital settings varies according to local TB prevalence. For instance
an university hospitals in Paris (France), reported MDR rates of respectively 1.2% among TB
cases [117], while in university hospitals in Manila (Philippine), this figure was an alarming
53.5% [118].
It is generally thought that the emergence of drug-resistant TB (usually termed acquired)
occurs in settings where patients fail to adhere to proper treatment regimens or receive
inadequate treatment. It is difficult to assign the current magnitude of the epidemic to acquired
resistance alone. Another mechanism for the perpetuation of resistance, which has largely been
neglected in the development of TB control programmes, is the direct transmission of drug-
resistant strains (called primary or transmitted resistance) [119]. In the 2006 XDR-TB outbreak
in KwaZulu-Natal (South Africa), 52 of 53 people who contracted the disease (all of them HIV
infected) died within weeks [120]. This outbreak received international attention because 85
percent of infected patients had genetically similar XDR strain, indicating that resistance was
likely transmitted rather than acquired. Consistent with these findings, a study conducted in
Tomsk (Siberia) –a setting where HIV infection is not widespread and effective TB treatment
is available– to identify factors leading to increases in MDR-TB cases [121], revealed that a
patient was six times more likely to develop MDR-TB if hospitalized for drug-susceptible TB
than if not hospitalized. These results strongly suggest that nosocomial transmission of TB
rather than resistance (acquired predominantly by nonadherence) is increasingly responsible
for the rising MDR TB case rates in Russia and probably in many other places.
Management of Drug-Resistant TB
http://dx.doi.org/10.5772/55531
223
Worthy of note is that nosocomial transmission of TB is a risk not only to inpatients but also
health care workers (HCWs). In fact, early studies revealed transmission of MDR-TB from
patient  to  patient  and  from  patient  to  HCWs  [122].  A  systematic  review  by  Joshi  and
colleagues [123] demonstrated that TB is a significant occupational problem among HCWs
in many low- and middle-income countries and that most health care facilities in these sittings
lack  resources  to  prevent  nosocomial  transmission  of  TB.  HIV-infected  HCWs  have  a
particularly high risk of TB, which may be fatal if the disease is caused by a drug-resistant
strain [124].  Indeed, dramatic nosocomial outbreaks of MDR TB occurred the late 1980s,
largely in HIV infected HCWs, and caused many deaths [110]. This situation increased the
concern  of  HCWs about  the  safety  of  working  in  institutions  with  a  large  numbers  of
admissions for active TB. Indeed, it is estimated that 1% to 10% of HCWs are infected annually
in hospitals with more than 200 admissions per year for TB [110]. The risk of TB transmis‐
sion to HCWs is particularly high in certain areas of the hospital, such as emergency rooms
and units that admit patients with active TB [125].
A review of several reports of TB outbreaks with transmission to HCWs in industrialized
countries revealed that many factors contribute to nosocomial transmission, such as delayed
diagnosis, poor ventilation with positive pressure in isolation rooms, aerosolization of bacilli
through mechanical ventilation, bronchoscopy and dressing change [110]. There was also
strong evidence that technicians involved in cough-inducing procedures, histologic prepara‐
tions and autopsies are at high risk, even in institutions caring for few patients with TB [126].
These outbreaks revealed many deficiencies in the knowledge of TB and its transmission as
well as strategies used to control the disease. Therefore, various health authorities have
implemented effective control programmes based on the early detection of TB and the prompt
isolation and treatment of persons with TB in addition to introducing strong measures to
prevent nosocomial transmissions of TB. For instance, the US Centers for Disease Control
(CDC) [127] recommended the following levels of controls: 1. Administrative controls, which
reduce risk of exposure. 2. Environmental controls, which prevent spread and reduce
concentration of droplet nuclei. 3. Respiratory-protection controls, which further reduce risk
of exposure in special areas and circumstances. (Box 6).
Implementation of a full hierarchy of these measures lead to a significant reduction in
nosocomial transmission of TB in the United States [128]. Whereas the extent of the epidemics
in low and middle income countries is still attributed, in large part, to ineffective transmission
control strategies. In these countries, double infection with TB and HIV has further accelerated
the transmission of drug resistant TB and increased the spread of HIV. Such a dramatic
situation blocks the efforts of both the Stop TB Partnership and anti-retroviral therapy
programmes. It is regrettable that many health care institutions continue to house HIV positive
individuals with patients who have drug-resistant TB, thus leading to nosocomial transmission
with subsequent community transmission. In this regards, health authorities in Haiti imple‐
mented an effective community-based transmission control programme with a baseline triage
and separation strategy [111]. Patients are admitted to either the general medical ward, a TB
pavilion, or very basic isolation rooms based on smear results and HIV status (Fig. 2).
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Figure 2. Community-based TB treatment triage strategy in Haiti. The general medical ward has natural ventila‐
tion and UV air disinfection. The TB ward has natural ventilation with fenestrated brick and more UV fixtures to disin‐
fect the air than the general ward has. The six isolation rooms are off a common corridor, and each has a large exhaust
fan built into the wall that draws air into the room from the corridor, as well as a UV fixture. Reprinted from Ref. 111
with permission of the International Union Against Tuberculosis and Lung Disease. Copyright © The Union
Although this simple baseline strategy is not sufficient, Nardell considers that its implement‐
ing in other resource-poor settings would contribute significantly to reduce the burden of TB
epidemic [111].
Administrative Controls
• Assign responsibility for TB infection control • Conduct TB risk assessment • Develop and institute a written TB
infection-control plan • Ensure the timely availability of recommended laboratory processing, testing, and reporting of
results
• Implement effective work practices for the management of patients with suspected or confirmed TB disease •
Ensure proper cleaning and sterilization or disinfection of potentially contaminated equipment • Train and educate
health-care workers • Test and evaluate health-care workers for TB infection and disease • Apply epidemiology-based
prevention principles • Use posters and signs demonstrating and advising respiratory hygiene and cough etiquette •
Coordinate efforts with the local or state health department.
Environmental Controls
Reduce concentration of infectious droplet nuclei through the following technologies:
• Ventilation technologies (Natural ventilation and Mechanical ventilation) • High efficiency particulate air filtration •
Ultraviolet germicidal irradiation
Respiratory Protection Controls
• Implement a respiratory-protection programme • Train health-care workers on respiratory protection • Educate
patients on respiratory hygiene and the importance of covering their cough • Test HCWs for mask fit and functionality
Box 6. TB Infection-Control Programme: Level of Controls
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12. Conclusion
Founded in 2001, the goal of The Stop TB Partnership for 2015 was to reduce the global burden
of TB disease (deaths and prevalence) by 50% relative to 1990 levels. The reality of the global
incidence of all forms of TB in 2012 indicates that this timetable is unrealistic. Despite billions
of dollars already spent on TB control programs, less than 2% of drug resistant TB cases
currently receive appropriate treatment in high burden countries allowing the disease to
spread faster than the implementation of adequate management programs. This dramatic
situation severely attenuates global efforts to control TB.
One of the major challenges now is to develop innovative approaches to expand the detection
and treatment of drug resistant cases globally. To achieve this goal, substantial funding and
development of extensive human resources is needed. Among the response priorities, the
following are of paramount importance: 1) developing tools for rapid detection of drug
resistance; 2) clinical trials to test simplified, safe and shorter second-line treatment regimens;
3) developing approaches to enhance treatment adherence; 4) clinical trials to test the efficacy
of new prophylactic treatment regimens for contacts of patients; and finally 5) developing safe
and more efficient second-line drugs.
However, even with increased detection and treatment of drug resistant TB, focusing on the
care of TB and neglecting living conditions in low-income countries has little chance of
completely reversing the burden of TB. The severity of the TB epidemic in the Western world
during the 19th century was largely due to the low living standards prevalent among the poor
during the industrial revolution. As living standards improved, TB mortality began to decrease
long before any vaccinations or specific therapy was introduced. Reminiscent of the 19th
century situation is the persistence of TB in poor and marginalized populations in most modern
cities of the world. As the British historian Thomas Mc-Keown said in 1976, “the overall health
of the population is less related to medical advances than to standards of living and nutrition”
[101]. Thus the control and eventual eradication of the TB epidemic will need support and
cooperation from multiple levels within the medical and scientific community, as well as all
levels of government worldwide in order to address living standards and develop better drugs
and therapeutic tools for the clinic.
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